

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

authorization with the Russian Ministry of Public Health for the use of Oncophage(R) (vitespen) in the treatment of kidney cancer patients at intermediate risk for disease recurrence. This submission contains final investigator-reported results from the largest, randomized, Phase 3 kidney cancer trial ever completed in the adjuvant treatment setting. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated August 2, 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTIGENICS INC.

Date: August 2, 2007

By: /s/ Garo H. Armen

Garo H. Armen, Ph.D.
Chairman and Chief Executive Officer

EXHIBIT INDEX

Exhibit No. -----	Description of Exhibit -----
99.1	Press Release dated August 2, 2007